CARGO Therapeutics Management
Management criteria checks 0/4
CARGO Therapeutics' CEO is Gina Chapman, appointed in May 2022, has a tenure of 2.67 years. total yearly compensation is $4.99M, comprised of 10.9% salary and 89.1% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth $1.54M. The average tenure of the management team and the board of directors is 1.4 years and 1.7 years respectively.
Key information
Gina Chapman
Chief executive officer
US$5.0m
Total compensation
| CEO salary percentage | 10.9% |
| CEO tenure | 2.7yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.4yrs |
| Board average tenure | 1.7yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$154m |
| Jun 30 2024 | n/a | n/a | -US$148m |
| Mar 31 2024 | n/a | n/a | -US$121m |
| Dec 31 2023 | US$5m | US$542k | -US$98m |
| Sep 30 2023 | n/a | n/a | -US$80m |
| Jun 30 2023 | n/a | n/a | -US$57m |
| Mar 31 2023 | n/a | n/a | -US$46m |
| Dec 31 2022 | US$825k | US$333k | -US$41m |
Compensation vs Market: Gina's total compensation ($USD4.99M) is above average for companies of similar size in the US market ($USD3.21M).
Compensation vs Earnings: Gina's compensation has increased whilst the company is unprofitable.
CEO
Gina Chapman (57 yo)
2.7yrs
Tenure
US$4,992,389
Compensation
Ms. Gina Chapman serves as Independent Director of Entrada Therapeutics, Inc. since September 01, 2023. She is President, Chief Executive Officer and Director of Cargo Therapeutics, Inc from May 02, 2022....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.7yrs | US$4.99m | 0.23% $ 1.5m | |
| Co-Founder & Scientific Advisory Board Chair | no data | US$160.00k | 0.061% $ 412.5k | |
| CFO, Secretary & COO | 2.4yrs | US$2.51m | 0.014% $ 95.3k | |
| Chief Medical Officer | 1.3yrs | US$2.63m | 0% $ 0 | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Senior Vice President of Finance & Accounting | 1.4yrs | no data | no data | |
| Chief Technical Officer | 3yrs | US$693.19k | 0.064% $ 436.0k | |
| Chief Scientific Officer | 1.4yrs | no data | no data | |
| Chief Legal Officer | 1.4yrs | no data | no data | |
| Head of Marketing | 1.3yrs | no data | no data |
1.4yrs
Average Tenure
56yo
Average Age
Experienced Management: CRGX's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.7yrs | US$4.99m | 0.23% $ 1.5m | |
| Co-Founder & Scientific Advisory Board Chair | less than a year | US$160.00k | 0.061% $ 412.5k | |
| Co-Founder & Scientific Advisory Board Member | 1.1yrs | no data | no data | |
| Independent Chairman of the Board | 2.3yrs | US$818.60k | 0% $ 0 | |
| Independent Director | 1.5yrs | US$514.13k | 0% $ 0 | |
| Independent Director | 1.8yrs | US$303.97k | 0% $ 0 | |
| Board Observer | no data | no data | no data | |
| Member Scientific Advisory Board | 1.1yrs | no data | no data | |
| Director | 3.9yrs | US$306.39k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$441.51k | 0% $ 0 | |
| Board Observer | no data | no data | no data | |
| Member of Scientific Advisory Board | 1.1yrs | no data | no data |
1.7yrs
Average Tenure
52yo
Average Age
Experienced Board: CRGX's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 02:54 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CARGO Therapeutics, Inc. is covered by 8 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Robert Burns | H.C. Wainwright & Co. |
| Michael Yee | Jefferies LLC |